20 Jul Parcel Bio
Posted at 21:04h
in
Christopher Carlson, Chief Scientific Officer
Oct. 5 | 1:45pm | FLW Ballroom G
San Francisco, CA
(Private)
ParcelBio is engineering a new class of mRNA medicines designed to deliver unprecedented potency and durability. Its proprietary APEXm™ platform uses novel RNA domains to enhance protein expression and extend activity, enabling therapies that reach the thresholds required for meaningful, and potentially curative, clinical outcomes. The company is advancing programs in autoimmune disease, oncology, and encoded protein therapeutics.